Psoralidin is a prenylated coumestan isolated primarily from Psoralea corylifolia (Babchi). It is not a classical anticancer drug.
Psoralidin generally acts to suppress oncogenic signaling and survival pathways while promoting apoptosis in tumor cells.
Reported effects (context-dependent, preclinical):
-DOWNREGULATES pro-survival pathways (e.g., NF-κB, STAT3)
-UPREGULATES apoptotic signaling (caspase activation)
-MODULATES androgen receptor signaling in prostate cancer models
-SENSITIZES tumor cells to chemo- and radio-induced stress
This positions psoralidin as a biologic modulator, not a driver.
Across cancer cell and animal models, psoralidin has been associated with:
-Apoptosis induction
-Caspase activation
-Mitochondrial depolarization
-Inflammatory pathway suppression
-NF-κB inhibition
-STAT3 attenuation
-Hormone signaling modulation
-Androgen receptor suppression (prostate cancer context)
-Oxidative stress interaction
-Redox imbalance tipping tumor cells toward death under stress
Psoralidin is best described as chemopreventive or chemo-sensitizing, not chemoprotective
|